Summary
This 2017 multi-centre study investigated whether molecular subtypes of muscle-invasive bladder cancer could improve prediction of chemotherapy response and survival outcomes in patients receiving neoadjuvant chemotherapy. The research brought together data from multiple institutions and cohorts to evaluate whether molecular profiling might refine patient stratification beyond conventional clinical and pathological variables. The findings, as suggested by the authorship and scope, contribute to precision oncology approaches in bladder cancer management.
UK applicability
The study's international authorship and multi-centre design (including European institutions) suggest findings may be applicable to UK bladder cancer services. However, applicability would depend on whether UK laboratories adopt the molecular classification approaches and whether cost–benefit analyses support implementation within NHS practice.
Key measures
Molecular subtype classification; chemotherapy response rates; pathological complete response; overall and disease-free survival; prognostic and predictive accuracy of molecular subtypes
Outcomes reported
The study examined how molecular subtypes of muscle-invasive bladder cancer predict response to neoadjuvant chemotherapy and overall survival outcomes. As suggested by the title, the research assessed associations between molecular classification and clinicopathological response following chemotherapy treatment.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.